Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Joshua M. Cohen's publication output changed over time?
ScholarIQpublication output · 1980–2021
Output grew100% over the shown period — from 1 works in 1980 to 2 in 2021.
1
1
2
2
3
2
198020112018201920202021
What are the most-cited papers on Joshua M. Cohen?
ScholarIQmost cited works
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning, Maja Galić, Joshua M. Cohen, Ronghua Yang, Matthias Müeller, Andrew H. Ahn, Yael Carmeli Schwartz, Melissa Grozinski‐Wolff, Lindsay Janka, Messoud Ashina
The Lancet. 2019438 Citations
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia
The Lancet Oncology. 2021401 Citations
Long-term safety, tolerability, and efficacy of fremanezumab in migraine
Peter J. Goadsby, Stephen D. Silberstein, Paul Yeung, Joshua M. Cohen, Xiaoping Ning, Ronghua Yang, David W. Dodick
Neurology. 2020178 CitationsOPEN ACCESS
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
Stephen D. Silberstein, Joshua M. Cohen, Michael J. Seminerio, Ronghua Yang, Sait Ashina, Zaza Katsarava
S143427143. 2020130 CitationsOPEN ACCESS
Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine
Stephen D. Silberstein, Lulu Lee, Kavita Gandhi, Timothy Fitzgerald, Jvawnna Bell, Joshua M. Cohen
Headache The Journal of Head and Face Pain. 2018103 Citations
Related on ScholarIQ
Gynecologic Oncology Group
Institution
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Paper
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
Paper
Long-term safety, tolerability, and efficacy of fremanezumab in migraine
Paper
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study
Paper
Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine
Paper